Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut ...

The list includes Novo Nordisk’s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, ...

Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...